EMILY BRAVO: Open Payments
NPI 1659880532 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,020 in 102 payments from 20 companies in 2025. Trend: 2023 $640 · 2024 $1,217 · 2025 $2,020
Food & beverage: $2,020
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $506 |
| Janssen Biotech, Inc. | 12 | $367 |
| Madrigal Pharmaceuticals | 7 | $152 |
| PFIZER INC. | 7 | $137 |
| Intercept Pharmaceuticals, Inc. | 5 | $106 |
| Celltrion USA Inc. | 4 | $106 |
| Lilly USA, LLC | 4 | $92 |
| Gilead Sciences, Inc. | 5 | $92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $63 |
| Ipsen Biopharmaceuticals, Inc | 2 | $59 |
Products named: TREMFYA, RINVOQ, REZDIFFRA, OCALIVA, VEGZELMA, OMVOH, VIBERZI, XELJANZ.
Industry payments across VA — which companies pay providers there.
